iGlarLixi (insulin glargine/lixisenatide)
Sponsors
Sanofi, Shanghai Zhongshan Hospital
Conditions
Type 2 DiabetesType 2 Diabetes (T2D)
Phase 4
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
RecruitingNCT06671587
Start: 2024-12-10End: 2026-09-18Target: 678Updated: 2026-03-17
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
CompletedNCT06716424
Start: 2025-01-06End: 2026-06-12Updated: 2026-07-10
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
RecruitingNCT07307235
Start: 2025-12-13End: 2027-12-30Target: 1316Updated: 2026-07-07